MX368508B - Benralizumab para usarse en la reducción de la tasa de exacerbación de asma. - Google Patents

Benralizumab para usarse en la reducción de la tasa de exacerbación de asma.

Info

Publication number
MX368508B
MX368508B MX2016001383A MX2016001383A MX368508B MX 368508 B MX368508 B MX 368508B MX 2016001383 A MX2016001383 A MX 2016001383A MX 2016001383 A MX2016001383 A MX 2016001383A MX 368508 B MX368508 B MX 368508B
Authority
MX
Mexico
Prior art keywords
asthma
methods
benralizumab
exacerbation rates
reducing exacerbation
Prior art date
Application number
MX2016001383A
Other languages
English (en)
Other versions
MX2016001383A (es
Inventor
Wang Bing
Roskos Lorin
Ward Christine
Raible Donald
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2016001383A publication Critical patent/MX2016001383A/es
Publication of MX368508B publication Critical patent/MX368508B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una cantidad efectiva de benralizumab para usarse en el tratamiento de asma, en donde el benralizumab está adaptado para ser administrable a un paciente con asma, en donde la administración reduce la tasa de exacerbación del paciente, y en donde el benralizumab está adaptado para ser administrable a una dosis de 30 mg una vez cada cuatro semanas durante doce semanas y luego una vez cada ocho semanas.
MX2016001383A 2013-08-12 2014-08-07 Benralizumab para usarse en la reducción de la tasa de exacerbación de asma. MX368508B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
PCT/US2014/050080 WO2015023504A1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab

Publications (2)

Publication Number Publication Date
MX2016001383A MX2016001383A (es) 2016-08-03
MX368508B true MX368508B (es) 2019-10-07

Family

ID=52448837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001383A MX368508B (es) 2013-08-12 2014-08-07 Benralizumab para usarse en la reducción de la tasa de exacerbación de asma.

Country Status (25)

Country Link
US (2) US9441037B2 (es)
EP (1) EP3033101B1 (es)
JP (3) JP6746495B2 (es)
KR (2) KR102390714B1 (es)
CN (2) CN111588848A (es)
AU (2) AU2014306956B2 (es)
BR (1) BR112016002401A8 (es)
CA (1) CA2918105C (es)
CY (1) CY1122132T1 (es)
DK (1) DK3033101T3 (es)
ES (1) ES2716906T3 (es)
HK (2) HK1221644A1 (es)
HR (1) HRP20190405T1 (es)
HU (1) HUE042607T2 (es)
LT (1) LT3033101T (es)
ME (1) ME03348B (es)
MX (1) MX368508B (es)
PL (1) PL3033101T3 (es)
PT (1) PT3033101T (es)
RS (1) RS58404B1 (es)
RU (1) RU2676333C2 (es)
SG (2) SG10202005560UA (es)
SI (1) SI3033101T1 (es)
TR (1) TR201903312T4 (es)
WO (1) WO2015023504A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057065T2 (hu) * 2013-08-12 2022-04-28 Astrazeneca Ab Eljárások asztma tüneteinek javítására benralizumab alkalmazásával
LT3033104T (lt) * 2013-08-12 2019-06-25 Astrazeneca Ab Būdai, skirti astmatikų priverstinio iškvėpimo tūrio padidinimui naudojant bendralizumabą
EP3057609A4 (en) * 2013-10-15 2017-03-22 Medlmmune, LLC Methods for treating chronic obstructive pulmonary disease using benralizumab
CN113350278B (zh) * 2013-10-24 2023-03-24 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
CN106103480B (zh) 2014-01-10 2021-10-22 安奈普泰斯生物有限公司 针对白介素-33(il-33)的抗体
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
EP3371225A2 (en) 2015-11-04 2018-09-12 AstraZeneca AB Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
AU2018206358B2 (en) 2017-01-04 2021-05-27 Worg Pharmaceuticals (Zhejiang) Co., Ltd. S-Arrestin peptides and therapeutic uses thereof
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010354A1 (en) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
JPWO2005035583A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 Ｉｌ−５受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
ES2558689T3 (es) * 2007-05-14 2016-02-08 Medimmune, Llc Métodos para reducir los niveles de eosinófilos
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
EP2501228A4 (en) * 2009-11-18 2013-11-13 Medicinova Inc TREATMENT OF ACUTE ASTHMA CRISIS AND REDUCTION OF THE PROBABILITY OF HOSPITALIZATION OF PATIENTS WITH SUFFERING
CN112168962A (zh) 2010-12-16 2021-01-05 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
CN104039352A (zh) 2011-11-01 2014-09-10 米迪缪尼有限公司 用于降低哮喘急性恶化的频率和严重性的方法
LT3033104T (lt) * 2013-08-12 2019-06-25 Astrazeneca Ab Būdai, skirti astmatikų priverstinio iškvėpimo tūrio padidinimui naudojant bendralizumabą
HUE057065T2 (hu) * 2013-08-12 2022-04-28 Astrazeneca Ab Eljárások asztma tüneteinek javítására benralizumab alkalmazásával

Also Published As

Publication number Publication date
RU2016108723A3 (es) 2018-06-18
EP3033101A1 (en) 2016-06-22
WO2015023504A8 (en) 2015-09-24
HK1225302B (zh) 2017-09-08
CY1122132T1 (el) 2020-11-25
JP6746495B2 (ja) 2020-08-26
CA2918105A1 (en) 2015-02-19
RS58404B1 (sr) 2019-04-30
BR112016002401A2 (pt) 2017-09-12
KR102390714B1 (ko) 2022-04-26
AU2014306956B2 (en) 2019-11-21
RU2676333C2 (ru) 2018-12-28
CN105451760A (zh) 2016-03-30
KR20160042121A (ko) 2016-04-18
TR201903312T4 (tr) 2019-04-22
DK3033101T3 (en) 2019-04-08
AU2014306956A1 (en) 2016-02-04
AU2020201327A1 (en) 2020-03-12
RU2016108723A (ru) 2017-09-19
SI3033101T1 (sl) 2019-04-30
ME03348B (me) 2019-10-20
HUE042607T2 (hu) 2019-07-29
ES2716906T3 (es) 2019-06-17
MX2016001383A (es) 2016-08-03
SG10202005560UA (en) 2020-07-29
PL3033101T3 (pl) 2019-06-28
EP3033101B1 (en) 2018-12-19
BR112016002401A8 (pt) 2018-06-12
LT3033101T (lt) 2019-03-25
US9441037B2 (en) 2016-09-13
HRP20190405T1 (hr) 2019-04-19
EP3033101A4 (en) 2017-07-12
US20170198049A1 (en) 2017-07-13
JP2016527324A (ja) 2016-09-08
PT3033101T (pt) 2019-04-02
US20150044202A1 (en) 2015-02-12
WO2015023504A1 (en) 2015-02-19
JP2020128375A (ja) 2020-08-27
JP2022120009A (ja) 2022-08-17
SG11201600481UA (en) 2016-02-26
KR20220057637A (ko) 2022-05-09
HK1221644A1 (zh) 2017-06-09
CN111588848A (zh) 2020-08-28
CA2918105C (en) 2023-02-28

Similar Documents

Publication Publication Date Title
MX368508B (es) Benralizumab para usarse en la reducción de la tasa de exacerbación de asma.
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
MX2016002571A (es) Regulador de ph de transduccion.
SG194701A1 (en) Anti-cd40 antibodies and methods of use
NZ707086A (en) Anti-cd40 antibodies and methods of use
PH12014502406B1 (en) Anti-il-23p19 antibodies
TN2012000462A1 (en) Anti-cd40 antibodies
PH12016501366A1 (en) Novel anti-baff antibodies
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX360774B (es) Antagonistas de progesterona.
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
MX2017014396A (es) Tratamiento de mieloma multiple.
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
MX2019009243A (es) Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa.
TN2013000265A1 (en) Anti-cd38 antibodies

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ASTRAZENECA AB

FG Grant or registration